Sampling malignant effusion such as ascites or pleural effusion is a relatively simple, minimally invasive, and repeatable procedure, and testing of effusion samples offers the distinct advantage of basing the HER2 assessment on the metastatic and, presumably, most aggressive clone of the tumor. The gene discussed is ERBB2; the disease is neoplasm.